TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23351460

Group type: EXPERIMENTAL
Intervention: Bilirubin level ≤0.6 mg/dl (group 1)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Bilirubin level >0.6 to 1.2 mg/dl (group 2)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Bilirubin level >1.2 mg/dl (group 3)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Log2 bilirubin (multivariate modeling)
Number of subjects: 1135
Study: 21069380

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 32
Study: 19690413

Group type: EXPERIMENTAL
Intervention: Milk supplemented with Lactobacillus rhamnosus LB21 (10(7) CFU/ml) and 2.5 mg fluoride per litre for lunch
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard milk
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Milk supplemented with Lactobacillus rhamnosus LB21 and fluoride
Number of subjects: 248
Study: 17459784

Group type: EXPERIMENTAL
Intervention: Behavioral intervention combining positive affect and self-affirmation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15669405

Group type: EXPERIMENTAL
Intervention: Conducting observations on a videotape of a confederate's performance
Number of subjects: 0
Study: 11703224

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (LDT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7960489

Group type: EXPERIMENTAL
Intervention: Thiamine treatment, 200 mg per day for 7 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non supplemented (CF2 group)
Number of subjects: 35
Study: 2958400

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms Hevac B vaccine at birth, 1, 2 and 14 months (Group I)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 5 micrograms Hevac B vaccine at birth, 2 and 14 months (Group II)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms Hevac B vaccine (Group I)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 5 micrograms Hevac B vaccine (Group II)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Comparison of anti-HBsAg positivity rates at birth
Number of subjects: 201

Group type: COMPARATOR
Intervention: Comparison of seroconversion rates at 2 months
Number of subjects: 201
Study: 29701040

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy at the points detected with thermosensitive moxibustion in Zhuang medicine combined with western medication (methotrexate, salazosulfapyridine, hydroxychloroquine, meloxicam)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Western medication (methotrexate, salazosulfapyridine, hydroxychloroquine, meloxicam)
Number of subjects: 168
Study: 27396518

Group type: EXPERIMENTAL
Intervention: BCG immunisation at birth (n=54)
Number of subjects: 98

Group type: COMPARATOR
Intervention: BCG immunisation at 2 months of age (n=44)
Number of subjects: 98
Study: 26611343

Group type: EXPERIMENTAL
Intervention: Video-otoscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional otoscopy
Number of subjects: 60
Study: 23902882

Group type: EXPERIMENTAL
Intervention: Shunting during carotid endarterectomy (CEA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No shunting during carotid endarterectomy (CEA)
Number of subjects: 180
Study: 19035084

Group type: EXPERIMENTAL
Intervention: Novel analgesic disposable Foley urinary catheter
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional F16 Foley urinary catheter
Number of subjects: 200
Study: 17035649

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Internet-based intervention
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (quarterly newsletters)
Number of subjects: 314
Study: 12791819

Group type: EXPERIMENTAL
Intervention: PET-derived flow reserve (FR) measurement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Plethysmography (PL)
Number of subjects: 10
Study: 11034644

Group type: EXPERIMENTAL
Intervention: Intradiscal electrothermal anuloplasty (IDTA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physical rehabilitation program (Control)
Number of subjects: 53
Study: 9331910

Group type: EXPERIMENTAL
Intervention: Event-related brain activation (ERBA) during target detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatio-temporal modelling of ERPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined fMRI and EEG methods
Number of subjects: 0
Study: 8365838

Group type: EXPERIMENTAL
Intervention: Shock absorbing heel inserts (SAH)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91
Study: 3466574

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) 60 mg/m2
Number of subjects: 79

Group type: COMPARATOR
Intervention: Doxorubicin (DX) 40 mg/m2
Number of subjects: 79
Study: 29308950

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise (CSE)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Body Awareness
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional Exercise (TE)
Number of subjects: 32
Study: 26691428

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 25038794

Group type: COMPARATOR
Intervention: Antibiotic alone (Group A)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Antibiotic plus supplement (Group B)
Number of subjects: 210
Study: 23397246

Group type: EXPERIMENTAL
Intervention: Cool Path Duo catheter (12-hole irrigated tip)
Number of subjects: 188
Study: 20390374

Group type: EXPERIMENTAL
Intervention: Heliosphere® bag (air-filled balloon, 960 cm3)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bioenterics‐BIB® (saline-filled balloon, 700 ml)
Number of subjects: 33
Study: 18216054

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy 160/4.5 microg twice daily and as needed
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Conventional best practice
Number of subjects: 1538
Study: 15705992

Group type: EXPERIMENTAL
Intervention: Bronchodilator inhalation (400 mug salbutamol by metered-dose inhaler)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bronchodilator inhalation
Number of subjects: 60
Study: 14516883

Group type: COMPARATOR
Intervention: Exhaled CO in patients with cardiomyopathy at rest
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exhaled CO in patients with cardiomyopathy 1 minute after exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exhaled CO in patients with cardiomyopathy 5 minutes after exercise
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Exhaled CO decrease in patients with cardiomyopathy after exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exhaled NO in patients with cardiomyopathy at rest
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exhaled NO in patients with cardiomyopathy 1 minute after exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exhaled NO in patients with cardiomyopathy 5 minutes after exercise
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Exhaled NO increase in patients with cardiomyopathy after exercise
Number of subjects: 37
Study: 10797781

Group type: EXPERIMENTAL
Intervention: Allevyn hydrocellular external application
Number of subjects: 3
Study: 8911239

Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 24

Group type: COMPARATOR
Intervention: H2 blockers
Number of subjects: 24
Study: 1588630

Group type: EXPERIMENTAL
Intervention: High-dosage methylprednisolone administered within 8 hours after injury
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3890730

Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g intravenously every 8 h)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g intravenously every 8 h) + Piperacillin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g intravenously every 8 h) + Tobramycin
Number of subjects: 21
Study: 30725362

Group type: EXPERIMENTAL
Intervention: Baclofen (18% of cohort, n = 115)
Number of subjects: 651
Study: 29370865

Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 3

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Food consumption
Number of subjects: 3
Study: 27061709

Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both treatments (SSCM and MANTRA)
Number of subjects: 142
Study: 23759829

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 22534136

Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (HT)
Number of subjects: 10
Study: 20367114

Group type: EXPERIMENTAL
Intervention: 50 mg IM dexketoprofen trometamol
Number of subjects: 70

Group type: COMPARATOR
Intervention: 75 mg IM diclofenac sodium
Number of subjects: 70
Study: 18630534

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy (TCM plaster sticking at Zhongwan (CV 12), Guanyuan (CV 4), Qihai (CV 6))
Number of subjects: 108

Group type: COMPARATOR
Intervention: Acupuncture therapy (simple acupuncture at Zhongji (CV 3), Guanyuan (CV 4), Qihai (CV 6))
Number of subjects: 108
Study: 16060181

Group type: EXPERIMENTAL
Intervention: Stapled rectal prolapse mucosectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open hemorrhoidectomy
Number of subjects: 100
Study: 12052586

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation
Number of subjects: 263

Group type: COMPARATOR
Intervention: Transcervical endometrial resection
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 263
Study: 10325837

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study: 8621847

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg once daily
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg once daily
Number of subjects: 279
Study: 1826243

Group type: EXPERIMENTAL
Intervention: Basal insulin (human ultralente insulin, n = 16)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Preprandial insulin (human unmodified insulin, n = 19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 35
Study: 6347356

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) alone, 70 mg/m2
Number of subjects: 109

Group type: COMPARATOR
Intervention: Combination of cisplatin (DDP) and cyclophosphamide, initial dose of cyclophosphamide 750 mg/m2
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 109

Group type: COMPARATOR
Intervention: Cisplatin (DDP) alone vs Combination therapy
Number of subjects: 109
Study: 31701026

Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) over the supplementary motor area (SMA)
Number of subjects: 0
Study: 29536332

Group type: EXPERIMENTAL
Intervention: Irradiation at a standard dose of 50 Gy in 25 fractions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Irradiation at a dose of 40.3 Gy in 13 fractions
Number of subjects: 60
Study: 27529612

Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Overall n-6 fatty acids
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Hospitalization and death events
Number of subjects: 297
Study: 25207393

Group type: EXPERIMENTAL
Intervention: Multi-atlas segmentation with level set-based local search
Number of subjects: 0
Study: 22480803

Group type: EXPERIMENTAL
Intervention: 30 mg/d duloxetine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 60 mg/d duloxetine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20479938

Group type: EXPERIMENTAL
Intervention: HIV‐1 DNA vaccine (VRC‐HVDNA 009‐00‐VP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17653993

Group type: EXPERIMENTAL
Intervention: Physiotherapy guided by musculoskeletal findings
Number of subjects: 22
Study: 16055648

Group type: EXPERIMENTAL
Intervention: Thought focus manipulation in Euro-Canadians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive future events in Euro-Canadians
Number of subjects: 0

Group type: COMPARATOR
Intervention: East Asians
Number of subjects: 0
Study: 12403738

Group type: EXPERIMENTAL
Intervention: Twice-weekly exercise class
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no exercise class)
Number of subjects: 93
Study: 10434213

Group type: EXPERIMENTAL
Intervention: Nellcor pulse oximeter with Oxismart signal processing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Criticareaverage21s (signal averaging time set at 21 seconds)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Criticareaverage3s (signal averaging time set at 3 seconds)
Number of subjects: 53
Study: 8846840

Group type: EXPERIMENTAL
Intervention: 100% O2 inhalation for 10 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5% CO2 with air inhalation for 10 min
Number of subjects: 10
Study: 2113543

Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 2 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1.0 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 2.0 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1.0 mg after placebo)
Number of subjects: 23
Study: 6250146

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study: 31303595

Group type: EXPERIMENTAL
Intervention: Antiviral (oseltamivir) alone
Number of subjects: 329

Group type: COMPARATOR
Intervention: Antiviral (oseltamivir) in combination with antibiotic
Number of subjects: 329
Study: 28214095

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (15mg/kg/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 40
Study: 25813217

Group type: COMPARATOR
Intervention: Avibactam 50, 100, 250, 500, 1000, 1500 or 2000 mg as a 30-min intravenous infusion (single ascending dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avibactam 250 mg with ceftazidime 1000 mg; Avibactam 500 mg with ceftazidime 2000 mg (second dose after washout)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avibactam 500, 750 or 1000 mg every 8 h over 5 days (multiple ascending doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam 2000-500 mg q8 h over 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avibactam 500 mg (single oral dose)
Number of subjects: 0
Study: 23660319

Group type: EXPERIMENTAL
Intervention: L + E (levodopa + entacapone)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: L (levodopa alone)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: L(−) (never on levodopa)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (people without PD or any other nervous system diseases)
Number of subjects: 240
Study: 21412224

Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 600 mg CBD
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19587369

Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: LSM plus MET
Number of subjects: 502

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 502

Group type: COMPARATOR
Intervention: Abnormal insulin resistance
Number of subjects: 502

Group type: COMPARATOR
Intervention: Abnormal DeltaI/G
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Normal beta-cell function with improved insulin sensitivity
Number of subjects: 502

Group type: COMPARATOR
Intervention: Deterioration in both insulin resistance and beta-cell function
Number of subjects: 502
Study: 17307037

Group type: EXPERIMENTAL
Intervention: Rocking biopsy forceps
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard biopsy forceps
Number of subjects: 32
Study: 16422975

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11565211

Group type: EXPERIMENTAL
Intervention: Lead STE (ST segment deviation in the single ECG lead of maximum ST deviation)
Number of subjects: 3593

Group type: EXPERIMENTAL
Intervention: Sum STR (sum of ST segment elevation resolution)
Number of subjects: 3593

Group type: EXPERIMENTAL
Intervention: Lead STR (ST segment resolution in the one lead showing maximal deviation)
Number of subjects: 3593

Group type: EXPERIMENTAL
Intervention: Lead STE
Number of subjects: 3593
Study: 9817300

Group type: EXPERIMENTAL
Intervention: Cisplatin combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-chemotherapy resection for residual masses
Number of subjects: 0
Study: 7875419

Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms, twice a day)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Ranitidine (300 mg per day)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 642

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 642
Study: 2832102

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: enalapril plus atenolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 28994661

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (120,000 IU/month)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Moderate-dose vitamin D3 (60,000 IU/month)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Standard-dose vitamin D3 (18,000 IU/month)
Number of subjects: 51
Study: 28807142

Group type: EXPERIMENTAL
Intervention: Lurasidone (40, 80, 120, or 160 mg/d)
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study: 26336883

Group type: EXPERIMENTAL
Intervention: Wii bowling intervention, played twice weekly for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 21761271

Group type: EXPERIMENTAL
Intervention: Original Hong Kong rule
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Modified rule (age ≤ 55 years)
Number of subjects: 148
Study: 21481649

Group type: EXPERIMENTAL
Intervention: Strong Non Painful TENS
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Sensory Threshold TENS
Number of subjects: 130

Group type: COMPARATOR
Intervention: Below Sensory Threshold TENS
Number of subjects: 130

Group type: COMPARATOR
Intervention: No Current Placebo TENS
Number of subjects: 130

Group type: COMPARATOR
Intervention: Transient Placebo TENS
Number of subjects: 130
Study: 18308094

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Photoselective vaporization (PVP)
Number of subjects: 76
Study: 17885292

Group type: EXPERIMENTAL
Intervention: DAPD + placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DAPD + MMF
Number of subjects: 40
Study: 15531667

Group type: EXPERIMENTAL
Intervention: Almond oil meal (30% energy from fat)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Control meal (fat as oil, 30% energy from fat)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole almond meal (30% energy from fat)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mixed-food test meals (all types)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Almond oil meal, Control meal, Whole almond meal
Number of subjects: 15
Study: 11177333

Group type: EXPERIMENTAL
Intervention: Inhaled insulin treatment before each meal plus a bedtime injection of ultralente insulin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inhaled insulin treatment
Number of subjects: 26
Study: 9046378

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 7712374

Group type: EXPERIMENTAL
Intervention: Moist ointment
Number of subjects: 115

Group type: COMPARATOR
Intervention: 0.25% iodophor
Number of subjects: 115

Group type: COMPARATOR
Intervention: Silver sulfadiazine paste
Number of subjects: 115

Group type: COMPARATOR
Intervention: 0.1% rivanol
Number of subjects: 115
Study: 3331039

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin 1 g q 8 h
Number of subjects: 38

Group type: COMPARATOR
Intervention: Aminoglycoside (tobramycin or netilmicin) plus amoxicillin 2 g q 8 h plus clindamycin 0.6 g q 6 h
Number of subjects: 38
Study: 30146969

Group type: EXPERIMENTAL
Intervention: Restrictive red‐cell transfusion strategy (transfusion if hemoglobin <7.5 g/dL)
Number of subjects: 5243

Group type: COMPARATOR
Intervention: Liberal red‐cell transfusion strategy (transfusion if hemoglobin <9.5 g/dL in ICU or <8.5 g/dL in non-ICU)
Number of subjects: 5243

Group type: EXPERIMENTAL
Intervention: Restrictive red‐cell transfusion strategy
Number of subjects: 5243

Group type: COMPARATOR
Intervention: Liberal red‐cell transfusion strategy
Number of subjects: 5243
Study: 26522742

Group type: EXPERIMENTAL
Intervention: Exercise under Hypoxia (EHG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exercise under Normoxia (ENG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hypoxia (HG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normoxia (NG)
Number of subjects: 40
Study: 25571209

Group type: EXPERIMENTAL
Intervention: Microbend fiber sensor
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard Polysomnography
Number of subjects: 22